The Bangladesh Association of Pharmaceutical Industries (BAPI) has accused the government of expanding the list of essential medicines and fixing their prices without consulting drug manufacturers. The allegation was raised on Saturday at a workshop titled “Bangladesh Pharma Industry: Present Challenges and Future Prospects,” jointly organized by BAPI and the Bangladesh Health Reporters Forum (BHRF) in Gazipur. BAPI leaders said the decision ignored production costs, international raw material prices, quality control, and market realities, posing long-term risks to medicine supply and industry stability.
BAPI Secretary General Dr. Md. Zakir Hossain criticized the policy process, saying no discussions were held with manufacturers or the association before the decision. He noted that the technical committee on pricing lacked members with real pharmaceutical experience. BAPI President Abdul Muktadir warned that about 60 percent of local drug companies are struggling, with nearly 40 percent already closed or near closure, threatening the country’s self-sufficiency in medicine. He urged government intervention to support small and medium firms and restore the industry’s health.
BAPI leaders also emphasized that Bangladesh’s pharmaceutical sector operates under strict regulatory oversight and called on journalists to highlight the challenges faced by struggling companies.
স্টাফ রিপোর্টার প্রকাশ : ১৭ জানুয়ারি ২০২৬, ২০: ৫২ স্টাফ রিপোর্টার ওষুধের দাম নির্ধারণে ওষুধ প্রস্তুতকারী প্রতিষ্ঠানগুলো মূল অংশীজন হলেও কোম্পানিগুলোর সঙ্গে কোনো ধরনের আলোচনা বা পরামর্শ ছাড়াই সরকার অত্যাবশ্যকীয় ওষুধের তালিকা সম্প্রসারণ ও দাম বেঁধে দি
The ‘1 Nojor’ media platform is now live in beta, inviting users to explore and provide feedback as we continue to refine the experience.
